76969-87-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl (S)-2-(Boc-aMino)-4-broMobutyrate is used as a building block for the synthesis of complex organic compounds, including peptides and pharmaceutical agents. Its versatility as a chemical reagent makes it valuable in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
Methyl (S)-2-(Boc-aMino)-4-broMobutyrate is used as a reagent in organic synthesis, where it can be incorporated into a wide range of chemical reactions to form various complex organic compounds. Its Boc-protected amino group and bromo-substituted butyrate chain make it a useful component in the synthesis of target molecules.
Used in Peptide Chemistry:
Methyl (S)-2-(Boc-aMino)-4-broMobutyrate is used in peptide chemistry as a building block for the synthesis of peptides. Its Boc-protected amino group allows for the controlled formation of peptide bonds, enabling the synthesis of larger and more complex peptide structures.

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 15159-66-7 α-amino-γ-bromobutyric acid methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101650-17-3 (S)-2-amino-4-bromobutyric acid methyl ester 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 75-65-0 tert-butyl alcohol 
• 120042-11-7 methyl (S)-4-hydroxy-2-((tert-butoxy)carbonylamino)-butyrate 
• 63491-82-7 tert-Butoxycarbonyl-L-homoserine DCHA salt 
• 177325-78-9 (2S)-2-amino-4-bromo-butyric acid methyl ester hydrobromide 
• 41088-86-2 L-2-(tert-butyloxycarbonylamino)-4-hydroxybutyric acid 
• 796072-25-8 (L)-N-tert-butoxycarbonylhomoserine triethylamine salt 

Downstream Products

• 64896-37-3 methyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-norvalinate 
• 182052-35-3 (S)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 168264-14-0 (S)-N-tert-butoxycarbonyl-γ-(N4-benzoxycarbonyl-1-cytosinyl)homoalanine 
• 194920-05-3 (S)-4-(6-Benzyloxycarbonylamino-purin-9-yl)-2-tert-butoxycarbonylamino-butyric acid 
• 194920-28-0 [(S)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-2-tert-butoxycarbonylamino-butyrylamino]-acetic acid 
• 194920-04-2 (S)-4-(6-Benzyloxycarbonylamino-purin-9-yl)-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 194920-07-5 (S)-4-[2-Amino-6-(2-nitro-phenoxy)-purin-9-yl]-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 194920-12-2 [(S)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-2-tert-butoxycarbonylamino-butyrylamino]-acetic acid ethyl ester 
• 194920-29-1 [(S)-4-(6-Benzyloxycarbonylamino-purin-9-yl)-2-tert-butoxycarbonylamino-butyrylamino]-acetic acid 
• 1026449-83-1 (S)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-2-tert-butoxycarbonylamino-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 194920-08-6 (S)-4-[2-Acetylamino-6-(2-nitro-phenoxy)-purin-9-yl]-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 194920-13-3 [(S)-4-(6-Benzyloxycarbonylamino-purin-9-yl)-2-tert-butoxycarbonylamino-butyrylamino]-acetic acid ethyl ester 
• 1026078-52-3 (S)-4-(6-Benzyloxycarbonylamino-purin-9-yl)-2-tert-butoxycarbonylamino-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 796072-26-9 4-(4'-bromobiphen-4-yloxy)-2-tert-butoxycarbonylaminobutyric acid methyl ester 

Relevant academic research and scientific papers

Synthesis and delivery of a stable phosphorylated ubiquitin probe to study ubiquitin conjugation in mitophagy

Protein post-translational modifications are involved in essentially all aspects of cellular signaling. Their dynamic nature and the difficulties in installing them using enzymatic approaches limits their direct study in human cells. Reported herein is the first synthesis, delivery and cellular study of a stable phosphoubiquitin probe. Our results compare Parkin's substrate preference during mitophagyviadirect visualization of a phosphorylated ubiquitin probe in the cellular environment.

Synthesis of Enantiopure Unnatural Amino Acids by Metallaphotoredox Catalysis

We describe herein a two-step process for the conversion of serine to a wide array of optically pure unnatural amino acids. This method utilizes a photocatalytic cross-electrophile coupling between a bromoalkyl intermediate and a diverse set of aryl halides to produce artificial analogues of phenylalanine, tryptophan, and histidine. The reaction is tolerant of a broad range of functionalities and can be leveraged toward the scalable synthesis of valuable pharmaceutical scaffolds via flow technology.

Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation

We report the design of hetero-bifunctional small molecules that selectively target p38α and p38β for degradation. These proteolysis targeted chimeras (PROTACs) are based on an ATP competitive inhibitor of p38α and p38β, which is linked to thalidomide analogues to recruit the Cereblon E3 ubiquitin ligase complex. Compound synthesis was facilitated by the use of a copper catalyzed “click” reaction. We show that optimization of the linker length and composition is crucial for the degradation-inducing activity of these PROTACs. We provide evidence that these chemical compounds can induce degradation of p38α and p38β but no other related kinases at nanomolar concentrations in several mammalian cell lines. Accordingly, the PROTACs inhibit stress and cytokine-induced p38α signaling. Our compounds contribute to understanding the development of PROTACs, and provide a useful tool to investigate functions of the p38 MAPK pathway and its involvement in diseases.

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

BORON-CONTAINING SMALL MOLECULES

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Nα-Fmoc-protected ω-azido- and ω-alkynyl-L- amino acids as building blocks for the synthesis of "clickable" peptides

The growing interest in the 1,4-disubstituted-1,2,3-triazolyl moiety as an amide bond surrogate and its formation through very mild, chemoselective, and bioorthogonal CuI-catalyzed Huisgen 1,3-dipolar [3+2] cycloaddition of an alkynyl to an azi

SUBSTITUTED AMINO CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

P38 inhibitors and methods of use thereof

This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.